Low-dose levonorgestrel and ethinyl estradiol patch and pill a randomized controlled trial

Obstetrics and Gynecology

Volumn 123, Issue 2, 2014, Pages 295-303

  Kaunitz, Andrew M ^{a,b,c,d,e,f,g}   Portman, David ^{a,b,c,d,e,f,g}   Westhoff, Carolyn L ^{a,b,c,d,e,f,g}   Archer, David F ^{a,b,c,d,e,f,g}   Mishell, Daniel R ^{a,b,c,d,e,f,g}   Rubin, Arkady ^{a,b,c,d,e,f,g}   Foegh, Marie ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Columbus Center for Women's Health Research ^*  (United States)

^c Department of Medicine   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f ARSTAT   (United States)

^g Agile Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ACNE; ADOLESCENT; ADULT; ARTICLE; BODY MASS; BREAST TENDERNESS; CONTRACEPTIVE PATCH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ETHNIC GROUP; FEMALE; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; PATIENT COMPLIANCE; PILL; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; UTERUS BLEEDING; YOUNG ADULT; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; OBESITY; PREGNANCY; TRANSDERMAL PATCH; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BODY MASS INDEX; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; ETHNIC GROUPS; FEMALE; HUMANS; LEVONORGESTREL; OBESITY; PATIENT COMPLIANCE; PREGNANCY; TRANSDERMAL PATCH; TREATMENT OUTCOME; UTERINE HEMORRHAGE; YOUNG ADULT;

EID: 84893817516     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000095     Document Type: Article

References (29)

1. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 2007;47:497-509.
2. van den HeuvelMW, van Bragt AJ, Alnabawy AK, KapteinMC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168-74.
3. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-46.
4. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004;69:189-95.
5. Archer DF, Stanczyk FZ, Rubin A, Foegh M. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: A randomized controlled trial. Contraception 2012;85:595-601.
6. Stanczyk FZ, Rubin A, Flood L, Foegh M. Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinyl estradiol and levonorgestrel. Horm Mol Biol Clin Invest 2011;6:231-40.
7. Pearl R. Factors in human fertility and their statistical evaluation. Lancet 1933;222:607-11.
8. Licea-Perez H, Wang S, Bowen CL, Yang E. A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852:69-76.
9. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
10. Grimes DA, Shields WC. Family planning for obese women: Challenges and opportunities. Contraception 2005;72:1-4.
11. Society of Family Planning, Higginbotham S. Contraceptive considerations in obese women: Release date 1 September 2009, SFP Guideline 20091. Contraception 2009;80:583-90.
12. Trussell J, Portman D. The creeping pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception 2013;88:604-10.
13. Audet MC, Moreau M, KoltunWD,Waldbaum AS, Shangold G, Fisher AC, et al; ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial. JAMA 2001;285:2347-54.
14. Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001;63:289-95.
15. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89-96.
16. Trussel J. Contraceptive failure in the United States. Contraception 2011;83:397-404.
17. Westhoff CL, Torgal AH, Mayeda ER, Stanczyk FZ, Lerner JP, Benn EK, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: A randomized controlled trial. Obstet Gynecol 2010;116:275-83.
18. Bleich SN, Thorpe RJ Jr, Sharif-Harris H, Fesahazion R, Laveist TA. Social context explains race disparities in obesity among women. J Epidemiol Community Health 2010;64:465-9.
19. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: The analysis of pooled data. Fertil Steril 2002;77(suppl 2):S13-8.
20. Kaneshiro B, Edelman A, Carlson N, Nichols M, Jensen J. The relationship between body mass index and unintended pregnancy: Results from the 2002 National Survey of Family Growth. Contraception 2008;77:234-8.
21. Westhoff CL, Hait HI, Reape KZ. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive. Contraception 2012;85:235-9.
22. Foegh M, Archer DF, Stanczyk FZ, Rubin A, Mishell DR Jr. Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. Contraception 2013;87:201-11.
23. Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A, et al. Hormonal contraceptives for contraception in overweight or obese women. The Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008452. DOI: 10.1002/14651858.CD008452.pub3.
24. Wan GJ, Barnowski CE, Ambegaonkar BM, Bolge SC, McDonnell DD. Treatment satisfaction with a transdermal contraceptive patch or oral contraceptives. Contraception 2007;75: 281-4.
25. Petitti DB. Hormonal contraceptives and arterial thrombosis-not risk-free but safe enough. N Engl J Med 2012;366:2316-8.
26. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002;106:1874-80.
27. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: Obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139:289-96.
28. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. Br Med J 1980;280: 1157-61.
29. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013;87: 93-100.